Elevation of plasma retinol-binding protein 4 and reduction of plasma adiponectin in subjects with cerebral infarction

Metabolism: Clinical and Experimental

Volumn 59, Issue 4, 2010, Pages 527-532

  Sasaki, Masami ^a,b   Otani, Taeko ^a   Kawakami, Masanobu ^a   Ishikawa, San e ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Hannou Municipal Naguri Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; RETINOL BINDING PROTEIN 4;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAIN INFARCTION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CEREBRAL INFARCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETINOL-BINDING PROTEINS, PLASMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949435819     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.08.015     Document Type: Article

References (45)

1. Yang Q., Graham T.E., Mody N., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436 (2005) 356-362
2. Quadro L., Blaner W.S., Salchow D.J., et al. Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. EMBO J 18 (1999) 4633-4644
3. Graham T.E., Yang Q., Blüher M., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354 (2006) 2552-2563
4. Takebayashi K., Suetsugu M., Wakabayashi S., et al. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 92 (2007) 2712-2719
5. Cho Y.M., Youn B.S., Lee H., et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 29 (2006) 2457-2461
6. Qi Q., Yu Z., Ye X., et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab 92 (2007) 4827-4834
7. Janke J., Engeli S., Boschmann M., et al. Retinol-binding protein 4 in human obesity. Diabetes 55 (2006) 2805-2810
8. Mody N., Graham T., Tsuji Y., et al. Decreased clearance of serum retinol binding protein and elevated levels of transthyretin in insulin-resistant ob/ob mice. Am J Physiol Endocrinol Metab 294 (2008) E785-E793
9. Stefan N., Hennige A.M., Staiger H.E., et al. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects: response to Broch et al. Diabetes Care 30 (2007) e91 [author reply e92]
10. Promintzer M., Krebs M., Todoric J., et al. Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab 92 (2007) 4306-4312
11. Lewis J.G., Shand B.I., Elder P.A., et al. Plasma retinol-binding protein is unlikely to be a useful marker of insulin resistance. Diabetes Res Clin Pract 80 (2008) e13-e15
12. Yao-Borengasser A., Varma V., Bodles A.M., et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 92 (2007) 2590-2597
13. Bajzová M., Kovaciková M., Vitková M., et al. Retinol-binding protein 4 expression in visceral and subcutaneous fat in human obesity. Physiol Res 57 (2009) 927-934
14. von Eynatten M., Lepper P.M., Liu D., et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 50 (2007) 1930-1937
15. Maeda K., Okubo K., Shimomura I., et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221 (1996) 286-289
16. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
17. Sasaki M., Kawano T., Saito T., et al. Hypoadiponectinemia in patients with cerebral infarction: comparison with other atherosclerotic disorders. Am J Med Sci 333 (2007) 140-144
18. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
19. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
20. Kawano T., Saito T., Yasu T., et al. Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metabolism 54 (2005) 653-656
21. Chen M.P., Tsai J.C., Chung F.M., et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 25 (2005) 821-826
22. Efstathiou S.P., Tsioulos D.I., Tsiakou A.G., et al. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 36 (2005) 1915-1919
23. Kubo M., Kiyohara Y., Kato I., et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 34 (2003) 2349-2354
24. Kitamura A., Iso H., Iida M., et al. Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med 112 (2002) 104-109
25. Nishizawa H., Shimomura I., Kishida K., et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51 (2002) 2734-2741
26. Bonora E., Formentini G., Calcaterra F., et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective d\ata from the Verona Diabetes Complications Study. Diabetes Care 25 (2002) 1135-1141
27. Hanley A.J., Williams K., Stern M.P., et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 25 (2002) 1177-1184
28. Folsom A.R., Rasmussen M.L., Chambless L.E., et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 22 (1999) 1077-1083
29. Matsumoto K., Miyake S., Yano M., et al. Insulin resistance and arteriosclerosis obliterans in patients with NIDDM. Diabetes Care 20 (1997) 1738-1743
30. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
31. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
32. Chen H., Montagnani M., Funahashi T., et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278 (2003) 45021-45026
33. Ouchi N., Kobayashi H., Kihara S., et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279 (2004) 1304-1309
34. Okamoto Y., Arita Y., Nishida M., et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32 (2000) 47-50
35. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
36. Arita Y., Kihara S., Ouchi N., et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105 (2002) 2893-2898
37. Yokota T., Oritani K., Takahashi I., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (2000) 1723-1732
38. Matsuda M., Shimomura I., Sata M., et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277 (2002) 37487-37491
39. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
40. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
41. Duncan B.B., Schmidt M.I., Pankow J.S., et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 53 (2004) 2473-2478
42. Kazumi T., Kawaguchi A., Sakai K., et al. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 25 (2002) 971-976
43. Iwashima Y., Katsuya T., Ishikawa K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43 (2004) 1318-1323
44. Nakamura T., Funayama H., Kubo N., et al. Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. Circ J 70 (2006) 1557-1562
45. Saito T., Saito O., Kawano T., et al. Elevation of serum adiponectin and CD146 levels in diabetic nephropathy. Diabetes Res Clin Pract 78 (2007) 85-92